Relypsa targets up to $150 million with IPO priced at $16 to $19

Drug developer Relypsa Inc. would raise up to $150 million at the top of the range of an initial public offering priced at $16 to $19 per share.

http://www.bizjournals.com/sanfrancisco/blog/biotech/2013/11/relypsa-ipo-rlyp-patiromer-hyperkalemia.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+vertical_37+%28Physician+Practices+Industry+News%29